Radiocirugía estereotáctica corporal en cáncer de pulmón no quirúrgico

Abstract

Stereotactic Body Radiosurgery (SBRT) in Non-Surgical Lung Cancer Introduction: In 2020, localized lung cancer was diagnosed in 4 million people, of whom 1.4 million passed away, and it is considered that by 2040, 6.2 million people will be diagnosed, according to estimates of the Global Cancer Observatory (Globocan). Early diagnosis of lung cancer improves the prognosis of the disease. Staging is essential to establish treatment. Non-surgical management options include stereotactic body radiosurgery, which is performed in patients not suitable for surgical intervention. Objective: To describe the treatment with stereotactic body radiosurgery in non-surgical lung cancer. Method: This is a narrative literature review study using an updated systematic search of scientific articles from high-impact scientific databases within the last five years about stereotactic body radiosurgery. Results: It is a treatment method used in early-stage non-small cell cancer (IT -T2) and oligometastatic disease with non-surgical evaluation. According to the studies, we have an overall survival at one year of 84.2% to 97.8%, and local control ranges from 87.4 to 97.4%. After five years, we will have an overall survival value of 82.6% and local control of 72.5% to 93.7%. Conclusions: This is a highly accurate radiotherapy technique that allows the administration of high doses of radiation in a reduced number of sessions, resulting in greater efficacy and lower toxicity, improving the quality of life and survival